PTP1B-IN-9 structure
|
Common Name | PTP1B-IN-9 | ||
---|---|---|---|---|
CAS Number | 145888-79-5 | Molecular Weight | 413.12500 | |
Density | N/A | Boiling Point | N/A | |
Molecular Formula | C19H13Cl4NO | Melting Point | N/A | |
MSDS | N/A | Flash Point | N/A |
Use of PTP1B-IN-9PTP1B-IN-9 is a ubiquitin-proteasome system (UPS)-stressor. PTP1B-IN-9 inhibits ubiquitin-mediated protein degradation upstream of the 20S proteasomal catalytic activites. PTP1B-IN-9 triggers a ubiquitin-proteasome-system (UPS)-stress response without affecting 20S proteasome catalytic activities. Anticancer activity[1]. |
Name | (3E,5E)-3,5-Bis(3,4-Dichlorobenzylidene)Piperidin-4-One |
---|
Description | PTP1B-IN-9 is a ubiquitin-proteasome system (UPS)-stressor. PTP1B-IN-9 inhibits ubiquitin-mediated protein degradation upstream of the 20S proteasomal catalytic activites. PTP1B-IN-9 triggers a ubiquitin-proteasome-system (UPS)-stress response without affecting 20S proteasome catalytic activities. Anticancer activity[1]. |
---|---|
Related Catalog | |
In Vitro | PTP1B-IN-9 (0-30 µM; 48 hours) treatment produces a dose dependent reduction in the viability of HPV16-positive SiHa and Caski cells and HPV-39-positive ME180 cervical cancer cell lines respectively[1]. PTP1B-IN-9 reduces the cell viability of exponentially growing HeLa cervical cancer cells in a dose-dependent fashion with an IC50 value of 2 µM[1]. Cell Viability Assay[1] Cell Line: Keratinocytes, SiHa, CaSki and ME180 cells Concentration: 5, 10, 15, 20, 25, 30 µM Incubation Time: 48 hours Result: Produced a dose dependent reduction in the viability of HPV16-positive SiHa and Caski cells and HPV-39-positive ME180 cervical cancer cell lines respectively with minimal effects on the viability of primary human keratinocytes and with IC50 similar to the obtained with HeLa cells. |
References |
Molecular Formula | C19H13Cl4NO |
---|---|
Molecular Weight | 413.12500 |
Exact Mass | 410.97500 |
PSA | 29.10000 |
LogP | 6.26830 |
Storage condition | 2-8°C |